NCT03042767View on ClinicalTrials.gov

Anti-LPS Antibody Treatment for Pediatric NAFLD

PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions

Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

BIOLOGICAL

IMM-124E

IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.

OTHER

Placebo

Matched Placebo

Trial Locations (1)

30322

Children's Healthcare of Atlanta, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Advanced MR Analytics AB

INDUSTRY

collaborator

Immuron Ltd.

INDUSTRY

lead

Miriam Vos, MD

OTHER

NCT03042767 - Anti-LPS Antibody Treatment for Pediatric NAFLD | Biotech Hunter | Biotech Hunter